Related Experiment Video
Updated: May 19, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Patient preferences and willingness to pay for different options of anticoagulant therapy
Marco Moia1, Lorenzo Giovanni Mantovani, Monica Carpenedo
1Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation, Via Pace 9, 20122, Milan, Italy.
Abstract:
New anticoagulant drugs alternative to vitamin K antagonists are currently under clinical evaluation. Patient's preferences should be considered in the development of new therapeutic strategies. Our study aim was to elicit patient preferences, and estimate their willingness to pay for the different treatment options. A Discrete Choice Experiment was administered to patients consecutively attending an anticoagulation clinic, either on stable oral anticoagulant therapy, or during their first visit at the time of starting therapy. Six treatment characteristics were analysed: route and number of medication administrations, frequency of monitoring, risk of some minor bleeding, the amount of attention required for drug/food interactions, requirement for dose adjustment, and out-of-pocket treatment cost. Relationships between patient's preferences and their characteristics were analysed. 255 patients participated (55 % men, with a mean age 64 years; 35.7 % on stable therapy). A statistically significant importance was attributed to all but two characteristics (the amount of attention required for interaction with other drugs/food and for dose adjustment.) Monthly patient willingness to pay was
Insights
Patients value convenience and safety in new anticoagulant drugs, showing a willingness to pay for features like oral administration and reduced monitoring. Preferences vary based on therapy status and patient demographics, guiding future treatment development.
Area of Science:
- Pharmacoeconomics
- Patient-centered care
- Anticoagulation therapy
Background:
- Novel oral anticoagulants (NOACs) are emerging as alternatives to vitamin K antagonists.
- Patient preferences are crucial for developing effective new therapeutic strategies.
- Understanding patient willingness to pay (WTP) can inform healthcare planning.
Purpose of the Study:
- To elicit patient preferences for different oral anticoagulant treatment characteristics.
- To estimate patient willingness to pay for various attributes of anticoagulant therapy.
- To analyze how patient characteristics influence treatment preferences.
Main Methods:
- A Discrete Choice Experiment (DCE) was administered to 255 patients at an anticoagulation clinic.
- Patients evaluated six treatment characteristics: administration route/frequency, monitoring, bleeding risk, interaction attention, dose adjustment, and cost.
- Statistical analysis explored relationships between patient demographics and preferences.
Main Results:
- All analyzed characteristics were significant except attention for drug/food interactions and dose adjustment.
- Patients showed a significant WTP for oral tablets over injections (
79/month), once-daily over twice-daily dosing ( 41/month), reduced bleeding risk ( 25/month), and less frequent monitoring ( 20/month). - Stable patients prioritized interaction attention; younger/working patients prioritized reduced monitoring frequency.
Conclusions:
- Patient preferences significantly influence the perceived value of anticoagulant therapies.
- DCE is a valuable method for quantifying patient preferences and WTP in anticoagulation.
- Findings provide essential data for optimizing healthcare planning and developing patient-centered anticoagulant strategies.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Venous Thrombosis IV: Nursing Management
Dosage Regimen: Individualization
